Rosiglitazone selectively inhibits K(ATP) channels by acting on the K(IR)6 subunit

BACKGROUND AND PURPOSE: Rosiglitazone is an anti-diabetic drug acting as an insulin sensitizer. We recently found that rosiglitazone also inhibits the vascular isoform of ATP-sensitive K(+) channels and compromises vasodilatory effects of β-adrenoceptor activation and pinacidil. As its potency for t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Yu, Lei, Jin, Xin, Cui, Ningren, Wu, Yang, Shi, Zhenda, Zhu, Daling, Jiang, Chun
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Publishing Ltd 2012
Aiheet:
Research Paper with Commentary
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3448911/
https://ncbi.nlm.nih.gov/pubmed/22394376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2012.01934.x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia